The estimated Net Worth of Wassim Fares is at least $160 dollars as of 10 September 2020. Wassim Fares owns over 4,000 units of Bellerophon Therapeutics Inc stock worth over $160 and over the last 4 years he sold BLPH stock worth over $0. In addition, he makes $0 as Chief Medical Officer. at Bellerophon Therapeutics Inc.
Wassim has made over 1 trades of the Bellerophon Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 4,000 units of BLPH stock worth $40,720 on 10 September 2020.
The largest trade he's ever made was buying 4,000 units of Bellerophon Therapeutics Inc stock on 10 September 2020 worth over $40,720. On average, Wassim trades about 2,000 units every 0 days since 2020. As of 10 September 2020 he still owns at least 4,000 units of Bellerophon Therapeutics Inc stock.
You can see the complete history of Wassim Fares stock trades at the bottom of the page.
Dr. Wassim Fares M.D. serves as Chief Medical Officer. of the Company. Dr. Fares is a board-certified pulmonologist and intensive care specialist with over 20 years of experience as a physician, principal investigator, associate professor, and pharmaceutical industry executive. Most recently, Dr. Fares was Senior Medical Director at Janssen Pharmaceutical Company and a member of Janssen's Pulmonary Hypertension therapeutic area development leadership team where he led developments across a broad range of potential indications, including fostering the design and execution of multiple Phase 1 through Phase 3 pivotal registration trials. Prior to Janssen, he consulted on clinical trial strategy for Actelion (Janssen/J&J), Bayer, Gilead, and United Therapeutics. Previously, Dr. Fares served in increasingly senior roles at Yale University, most recently as Director, a nationally-accredited Pulmonary Vascular Disease Center. Dr. Fares completed his post-graduate fellowship program in Pulmonary Disease and Critical Care Medicine at the University of North Carolina and his residency in Internal Medicine at St. Vincent Charity Medical Center. He earned medical and undergraduate degrees from the American University of Beirut, and a master's degree in clinical research from the University of North Carolina.
Wassim's mailing address filed with the SEC is 184 LIBERTY CORNER RD., SUITE 302, WARREN, NJ, 07059.
Over the last 10 years, insiders at Bellerophon Therapeutics Inc have traded over $8,853,497 worth of Bellerophon Therapeutics Inc stock and bought 9,412,012 units worth $57,370,250 . The most active insiders traders include Robert Nelsen, Adam Weinstein и Associates Iv L P Venrock H.... On average, Bellerophon Therapeutics Inc executives and independent directors trade stock every 61 days with the average trade being worth of $10,679. The most recent stock trade was executed by Capital Management Lp Puiss... on 13 October 2023, trading 1,076,841 units of BLPH stock currently worth $107,684.
bellerophon therapeutics is a clinical-stage biotherapeutics company focused on developing innovative products combining novel drugs and devices in the treatment of cardiopulmonary and cardiac diseases. our mission is to develop well-studied molecules deployed through innovative delivery systems to treat diseases with significant unmet clinical need.
Bellerophon Therapeutics Inc executives and other stock owners filed with the SEC include: